Hansa Biopharma appoints Fredrik Röök as VP Business Development

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Fredrik Röök has been appointed as VP Business Development effective 17th August. Mr Röök will report to CEO Renée Aguiar-Lucander

Fredrik Röök brings more than 20 years of experience in business development, licensing, and strategic transactions across the global life science industry. He joins Hansa from AstraZeneca, where he served as Senior Director, Global Business Development, leading complex partnering activities including M&A, in- and out-licensing, divestments, and strategic collaborations. He has a strong track record of executing transactions across all stages, from early innovation to commercial assets, across pharma, biotech, and venture-backed environments. Fredrik Röök holds an M.Sc. in Pharmacy from the University of Gothenburg and an MBA from Simon Fraser University.  

Renée Aguiar-Lucander, CEO of Hansa Biopharma said:

This is a strategic appointment as we prepare for the next phase of Hansa’s growth. Mr Röök is a highly qualified and proven business development leader with deep expertise in complex transactions, a strong strategic mindset, and a broad global network. He will play a key role as we advance our pipeline and pursue new strategic opportunities. His addition strengthens our capabilities further at a pivotal stage for the Company.

You may also like

Regulatory

Hansa Biopharma’s imlifidase BLA accepted for FDA review

The US Food and Drug Administration has accepted the company's Biologics License Application for imlifidase, a novel IgG-cleaving enzyme designed to enable HLA-incompatible kidney transplantation
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Ingredients

GELITA launches ultra-low endotoxin MEDELLAPRO grade targeting sensitive biomedical applications

The new gelatin excipient, featuring less than ten endotoxin units per gram, expands GELITA's ECE portfolio for drug delivery, vaccine stabilisation and 3D bioprinting, alongside recombinant animal-free collagen development
Manufacturing

Choosing a modular filter dryer with flexible vessel materials

Design teams in pharmaceutical and chemical research face mounting pressure to move faster without compromising precision or safety. The Agitated Nutsche Filter Dryer (ANFD) answers this challenge by combining filtration, washing, and drying into a single sealed process; helping protect operators, ensuring material containment, and driving consistency
Manufacturing

Marchesini Group unveils ORBITA-L filling and capping machine at Interpack 2026

New modular system combines intermittent-motion technology with magnetic transport for flexible liquid product filling and capping
Manufacturing

How particle size classification drives product consistency and quality in complex injectables

Pharmaceutical pipelines have shifted decisively toward complex drug delivery systems like long-acting injectables (LAIs), but this innovation poses new quality challenges
Manufacturing

Axplora consolidates UDCA manufacturing at FDA-approved Vizag site using green chemistry process

The transition from Gropello Cairoli to India frees Farmabios to focus on HPAPI and steroid leadership, while Vizag's enzymatic synthesis route and backwards-integrated bile sourcing strengthen global API supply resilience
Subscribe now